Free shipping on orders of $75+ for patients.
Doctors must be logged in to view professional pricing.
You are viewing professional pricing.

How Can IRPL® Technology Positively Impact Eye Care Professionals & Their Dry Eye Patients?

(I-MED Pharma)

Being able to offer patients innovative solutions that have long-lasting effects for their dry eye symptoms can change the scope of an eye care professional’s practice and take it to the next level.  With an estimated thirty percent of Canadians experiencing ocular symptoms associated with dry eye, there is an obvious need for effective solutions.

The main cause of evaporative dry eye is Meibomian Gland Dysfunction (MGD).  In MGD patients, the tear film becomes unstable, leading to an insufficient production, or an excessive evaporation of tears. These malfunctioning glands do not produce enough oils into the tears.  As a course of treatment for MGD, eye care professionals will often express these glands themselves, however, this is a manual process and can lead to inflammation.

Recently, Health Canada approved a long-lasting solution for dry eyes, called the E>Eye. Designed and manufactured in France, E>Eye is the first and only medical device in the world using Patented IRPL® Technology (Intense Regulated Pulsed Light), developed specifically for the treatment of dry eye disease caused by MGD.

IRPL® treatments are clinically tested with proven results.  Clinical studies show a considerable improvement in the symptoms perceived by patients, with a 90% satisfaction rate after the first 2 treatments.  Treatment sessions are quick, safe, effective, and painless. Watch our interview with Dr. Dash to learn more about his experience using this device.

Currently, there are IPL devices on the market that use old lamp technology with traditional type flashes that are divided into sub-pulses, which all have the same duration and light intensities. These devices are incompatible with neurological stimulation and have a much lower efficacy rate than the E>Eye.

The main advantage that IRPL® technology offers over traditional IPL treatments is its long-term effects in maintaining the meibomian gland function and improving its ability to produce oils within the tears.  This new type of polychromatic pulsed light produces perfectly calibrated and homogeneously sequenced “cold light” pulses.  These pulses safely stimulate the meibomian glands to resume secretions, improving the lacrimal film and significantly reducing the symptoms associated with ocular dryness.  Long-term benefits of 6-12 months are standard, with some patients experiencing even longer-lasting results.  Traditional IPL treatments can show some immediate improvements; however, these results tend to diminish quickly over time.

For eye care professionals, integrating the E>Eye device into their practice is simple and can have significant long-term benefits.  It is user-friendly and intuitive, with no risk for errors.  Treatment sessions can begin within a few seconds and take only 3 minutes to perform.  There is no pre-heating required and the device is compact, which allows it to fit into any practice space.

E>Eye is available to eye care professionals in Canada, exclusively through I-MED Pharma.